PDUFA VII: Drug application fees increase by 25% in first year of new five-year deal
The FDA unveiled its user fee rates for prescription drugs, biosimilars, generics and medical devices last Friday — and with the exception of biosimilar applicants, sponsors …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
